Michael Hallek, MD

Faculty of Medicine and University Hospital Cologne
Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
Cologne, Germany

N/A

Presentation(s):

• (1553624) LYN kinase and its regulator CSK as key players in CLL-supporting macrophages

  Friday, October 6, 2023
  8:10 AM – 8:20 AM EDT

• (1548041) Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia

  Saturday, October 7, 2023
  10:00 AM – 10:10 AM EDT

• (1541946) Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group

  Sunday, October 8, 2023
  9:15 AM – 9:25 AM EDT

• (1554032) Bendamustine, Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Updated Results of the CLL2-BAAG Trial of the German CLL Study Group (GCLLSG)

  Sunday, October 8, 2023
  2:55 PM – 3:05 PM EDT

• (1548000) Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with targeted drugs: pooled analysis of clinical trials from the German CLL Study Group (GCLLSG).

  Monday, October 9, 2023
  11:15 AM – 11:25 AM EDT